Month: June 2021

– CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors – – CFT8919 Demonstrates Intracranial Activity Pre-clinically, Indicating the Potential to be Effective Against CNS Metastases – – Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Development with IND Submission Expected in mid-2022 and Clinical Trial Initiation Expected by YE 2022 –  – Conference Call and Webcast at 8:00 am ET Today – WATERTOWN, Mass., June 07, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented new pre-clinical data on CFT8919, a novel mutant-selective degrader of epidermal growth factor receptor (EGFR)...

Figure 1Analytical Signal of the Total Magnetic Intensity, Iska Iska Property, Potosi Department, Southern BoliviaTORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Eloro Resources Ltd. (TSX-V: ELO; OTCQX: ELRRF FSE: P2QM) (“Eloro”, or the “Company”) is pleased to report results from its recently completely magnetics survey on the Company’s Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. A total of 181.5 linekm of magnetic data were collected on 50m spaced north-south lines on all of the accessible parts of the property. Figure 1 shows a map of the Analytic Signal (“ASIG”) of the Total Magnetic Intensity. The outline of the Iska Iska Caldera and major breccia pipe targets are overlain. This map combines the local rate of change of the magnetic field intensity in all directions to give a...

Figure 1: View of Boart Longyear RC drill rig setup at the first drill location.Figure 1: View of Boart Longyear RC drill rig setup at the first drill location.VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) — Scorpio Gold Corporation (“Scorpio Gold” or the “Company”) (TSXV: SGN) is pleased to announce the commencement of a 4,800 meter surface reverse circulation drilling program targeting high-grade mineralized zones intersected in historic drilling below the mined-out Manhattan East and West pits as well as investigate the continuity of mineralization extending northward from the West Pit toward the Goldwedge underground workings on the newly acquired Kinross Manhattan Property in Manhattan, Nevada. The drilling program commenced on the 1st of June with a total of 236 m of RC drilling completed on...

HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac catheterization, coronary artery disease and diagnostic angiography, which make his assistance an invaluable asset to Microbot as it continues to develop the LIBERTY™ Robotic System. Dr. Weisz performed the Corindus Vascular Robotics’ (acquired by Siemens Healthineers) First-in-Human (FIH) clinical trial to evaluate the safety and technical efficacy of Corindus’ CorePath...

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC; Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) is pleased to announce that, due to significant investor demand, it has increased the size of its previously announced non-brokered private placement (see news release dated May 6, 2021) to aggregate gross proceeds of up to $350,000 (the “Offering”). Closing of the Offering is expected to occur on or about June 10, 2021. The Offering will now be composed of (i) up to 5,100,000 flow-through shares (“FT Shares”) at a price of $0.05 per FT Share for gross proceeds of up to $255,000; and (ii) up to 1,900,000 hard dollar units (“HD Units”) at a price of $0.05 per HD Unit for gross proceeds of up to $95,000....

Equipment transfer positions Prodigy to expedite production expansion and next-generation disease-resistant silkworms ANN ARBOR, Mich., June 07, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the transfer of its onsite testing and screening of transgenics technology to Prodigy Textiles, the Company’s Vietnam based subsidiary. The Company made the significant decision to transfer testing and screening technologies from its R&D headquarters in the US to its factory in Vietnam. This testing equipment allows for precise screening and selection of the transgenics’ key genetic traits, which are currently conducted exclusively at the Company’s US headquarters. Implementing this...

Atlanta, June 07, 2021 (GLOBE NEWSWIRE) — Piedmont Office Realty Trust (the “Company” or “Piedmont”) (NYSE: PDM) announced today in advance of the National Association of Real Estate Investment Trusts’ Annual Investor Conference which begins on June 8th that it has completed approximately 230,000 square feet of leasing transactions during the Second Quarter of 2021 through May, with approximately 60% related to new tenant leasing. This completed leasing total excludes the progress on the previously-reported 5-year, 313,000 square foot renewal negotiation with the City of New York at 60 Broad Street, which cleared the final stage of the public hearing review process in late May and now awaits execution by the Mayor’s office. Commenting on recent leasing transactions, C. Brent Smith, President and Chief Executive Officer of Piedmont...

Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities STAMFORD, Conn., June 07, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaboration agreement with Seagen Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with SEA-BCMA, Seagen’s investigational monoclonal antibody targeting B-cell maturation agent (BCMA), in patients with relapsed or refractory multiple myeloma. Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells. In preclinical models, nirogacestat...

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study will evaluate pulmonary function, lung injury and edema formation, cardiopulmonary hemodynamics, and systemic vascular permeability. MediciNova has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential...